Home β€Ί Healthcare β€Ί Rare Diseases β€Ί Alpha-1 Antitrypsin Deficiency Treatment Market

Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share, Opportunities, And Trends By Treatment Type (Augmentation Therapy, Bronchodilator, Corticosteroids, Oxygen Therapy, Others), By Route of Administration (Parenteral, Inhalation, Oral), By End-user (Speciality clinics, Hospitals, Pharmacies, Others), And By Geography - Forecasts From 2024 To 2029

πŸ“₯ Download Free SampleπŸ’¬ Speak to Analyst
$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Table of Contents

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key Benefits for the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET BY TREATMENT TYPE

5.1. Introduction

5.2. Augmentation Therapy

5.2.1. Market Trends and Opportunities

5.2.2. Growth Prospects

5.2.3. Aralast

5.2.4. Prolastin

5.2.5. Raspreeza

5.2.6. Glassia

5.3. Bronchodilator

5.3.1. Market Trends and Opportunities

5.3.2. Growth Prospects

5.4. Corticosteroids

5.4.1. Market Trends and Opportunities

5.4.2. Growth Prospects

5.5. Oxygen Therapy

5.5.1. Market Trends and Opportunities

5.5.2. Growth Prospects

5.6. Others

5.6.1. Market Trends and Opportunities

5.6.2. Growth Prospects

6. ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET BY ROUTE OF ADMINISTRATION 

6.1. Introduction

6.2. Parenteral

6.2.1. Market Trends and Opportunities

6.2.2. Growth Prospects

6.3. Inhalations

6.3.1. Market Trends and Opportunities

6.3.2. Growth Prospects

6.4. Oral

6.4.1. Market Trends and Opportunities

6.4.2. Growth Prospects

7. ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET BY END-USER

7.1. Introduction

7.2. Speciality Clinics

7.2.1. Market Trends and Opportunities

7.2.2. Growth Prospects

7.3. Hospitals 

7.3.1. Market Trends and Opportunities

7.3.2. Growth Prospects

7.4. Pharmacies

7.4.1. Market Trends and Opportunities

7.4.2. Growth Prospects

7.5. Others

7.5.1. Market Trends and Opportunities

7.5.2. Growth Prospects

8. ALPHA-1 ANTITRYPSIN DEFICIENCY TREATMENT MARKET BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. By Treatment Type

8.2.2. By Route of Administration

8.2.3. By End-User

8.2.4. By Country

8.2.4.1. United States

8.2.4.1.1. Market Trends and Opportunities

8.2.4.1.2. Growth Prospects

8.2.4.2. Canada

8.2.4.2.1. Market Trends and Opportunities

8.2.4.2.2. Growth Prospects

8.2.4.3. Mexico

8.2.4.3.1. Market Trends and Opportunities

8.2.4.3.2. Growth Prospects

8.3. South America

8.3.1. By Treatment Type

8.3.2. By Route of Administration

8.3.3. By End-User

8.3.4. By Country 

8.3.4.1. Brazil

8.3.4.1.1. Market Trends and Opportunities

8.3.4.1.2. Growth Prospects

8.3.4.2. Argentina

8.3.4.2.1. Market Trends and Opportunities

8.3.4.2.2. Growth Prospects

8.3.4.3. Others

8.3.4.3.1. Market Trends and Opportunities

8.3.4.3.2. Growth Prospects

8.4. Europe

8.4.1. By Treatment Type

8.4.2. By Route of Administration

8.4.3. By End-User

8.4.4. By Country

8.4.4.1. United Kingdom

8.4.4.1.1. Market Trends and Opportunities

8.4.4.1.2. Growth Prospects

8.4.4.2. Germany

8.4.4.2.1. Market Trends and Opportunities

8.4.4.2.2. Growth Prospects

8.4.4.3. France

8.4.4.3.1. Market Trends and Opportunities

8.4.4.3.2. Growth Prospects

8.4.4.4. Italy

8.4.4.4.1. Market Trends and Opportunities

8.4.4.4.2. Growth Prospects

8.4.4.5. Spain

8.4.4.5.1. Market Trends and Opportunities

8.4.4.5.2. Growth Prospects

8.4.4.6. Others

8.4.4.6.1. Market Trends and Opportunities

8.4.4.6.2. Growth Prospects

8.5. Middle East and Africa

8.5.1. By Treatment Type

8.5.2. By Route of Administration

8.5.3. By End-User

8.5.4. By Country

8.5.4.1. Saudi Arabia

8.5.4.1.1. Market Trends and Opportunities

8.5.4.1.2. Growth Prospects

8.5.4.2. UAE

8.5.4.2.1. Market Trends and Opportunities

8.5.4.2.2. Growth Prospects

8.5.4.3. Others

8.5.4.3.1. Market Trends and Opportunities

8.5.4.3.2. Growth Prospects

8.6. Asia Pacific

8.6.1. By Treatment Type

8.6.2. By Route of Administration

8.6.3. By End-User

8.6.4. By Country

8.6.4.1. Japan

8.6.4.1.1. Market Trends and Opportunities

8.6.4.1.2. Growth Prospects

8.6.4.2. China

8.6.4.2.1. Market Trends and Opportunities

8.6.4.2.2. Growth Prospects

8.6.4.3. India

8.6.4.3.1. Market Trends and Opportunities

8.6.4.3.2. Growth Prospects

8.6.4.4. South Korea

8.6.4.4.1. Market Trends and Opportunities

8.6.4.4.2. Growth Prospects

8.6.4.5. Taiwan

8.6.4.5.1. Market Trends and Opportunities

8.6.4.5.2. Growth Prospects

8.6.4.6. Thailand

8.6.4.6.1. Market Trends and Opportunities

8.6.4.6.2. Growth Prospects

8.6.4.7. Indonesia

8.6.4.7.1. Market Trends and Opportunities

8.6.4.7.2. Growth Prospects

8.6.4.8. Others

8.6.4.8.1. Market Trends and Opportunities

8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Takeda Pharmaceutical Company Ltd.

10.2. Kamada Pharmaceuticals

10.3. Pfizer Inc.

10.4. Grifols

10.5. GlaxoSmithKline

10.6. CSL Behring

10.7. LFB Biomedicaments S.A.

REPORT DETAILS

Report ID:KSI061616837
Published:Mar 2024
Pages:147
Format:PDF, Excel, PPT, Dashboard
πŸ“₯ Download SampleπŸ“ž Speak to AnalystπŸ“§ Request Customization

Need Assistance?

Our research team is available to answer your questions.

Contact Us